Key facts
- This page summarizes Catherine M. Szyman's Form 4 filing for Edwards Lifesciences Corp (EW).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Sep 2024, 19:10.
Catherine M. Szyman - 03 Sep 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)
- Reporting relationship
- CVP, Critical Care
- Issuer ticker
- EW
- Reported as of
- 03 Sep 2024
- Net transaction value
- -$386,879
- SEC form
- 4
- Accepted by SEC
- 03 Sep 2024, 19:10:37 UTC
- Prior SEC filing
- 08 Jul 2024
- Next SEC filing
- 14 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- Linda J. Park, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Catherine M. Szyman filed Form 4 for Edwards Lifesciences Corp (EW) on 03 Sep 2024.
Change
- Previous filing in this sequence was filed on 08 Jul 2024.
- Current net transaction value: -$386,879.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EW
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,910
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 86,817
- Date
- 03 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
EW
transaction
Common Stock
Tax liability
- Transaction value
- $386,879
- Shares
- -5,530
- Change %
- -6.4%
- Price
- $69.96
- Shares after
- 81,287
- Date
- 03 Sep 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date.
SEC remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.